LifeStance Health Group Inc. Common Stock vs Personalis Inc. Common Stock — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.7 (market cap $4.69B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: LifeStance Health Group Inc. Common Stock is far larger — about 2.8× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is more actively traded (3,817,236 versus 1,858,220). Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 6 Days and Personalis Inc. Common Stock for 0 Days on average.
| LFST | PSNL | |
|---|---|---|
Market Cap | $4.69B | $1.69B |
Volume | 1,858,220 | 3,817,236 |
Sector | Health | Health |
52-Week High | $13.38 | $18.38 |
52-Week Low | $4.81 | $5.04 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.92B | $1.52B |
Signals from Pluang's Aura AI — not financial advice
LifeStance Health Group (LFST) trades at $12.32, down 1.28% today, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $0.06 exceeding the $0.03 forecast. Revenue growth accelerated from $1.42B in 2025 to $1.6B in 2026, while net income improved significantly from $9.66M to $51M.
Wall Street maintains strong bullish sentiment with 82% buy ratings and a $14.14 consensus price target representing 15% upside. However, elevated valuation multiples (P/E 94.8) and overbought technical conditions near 52-week highs warrant caution. The mental healthcare provider benefits from industry tailwinds but faces execution risks amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →